Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: Results of a phase i dose-escalating study in patients with advanced solid malignancies Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Lipids
  • Neoplasms

abstract

  • Hepato- and neuro-toxicity are schedule independent dose-limiting adverse events for this marine compound, as illustrated by this and other early clinical trials.

publication date

  • December 2011

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1007/s00280-011-1612-1

PubMed ID

  • 21465314

Additional Document Info

start page

  • 1397

end page

  • 403

volume

  • 68

number

  • 6